SCHEMBL4844097

SCHEMBL4844097

Cn1c[c]c2ccc(Cl)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 1/20 0.38
MAT2A P31153 1/20 0.33
HSD11B1 P28845 1/20 0.32
KMT2A Q03164 1/20 0.31
LMNA P02545 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TP53 P04637 1/20 0.31
IDO1 P14902 1/20 0.31
PTPN1 P18031 1/20 0.31
DAO P14920 1/20 0.31
KMO O15229 2/20 0.30
APOBEC3A P31941 1/20 0.30
APOBEC3G Q9HC16 1/20 0.30
NTRK1 P04629 1/20 0.30
CYP3A4 P08684 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
HSD17B10 Q99714 1/20 0.30
KDM4E B2RXH2 1/20 0.30
HCRTR1 O43613 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7386654 0.86 PSMB8 (0.33) PSMB8HSD11B1KMT2ALMNAL3MBTL1
SCHEMBL7836567 0.79 KDM4E (0.33) DAOAPOBEC3AAPOBEC3GKDM4EMAPT
SCHEMBL4850518 0.78 KDM4E (0.35) IDO1DAOHSD17B10KDM4E
SCHEMBL193935 0.71 GPR3 (0.37) SMN1; SMN2KDM4EMAPT
SCHEMBL4852140 0.71 AHR (0.32)
SCHEMBL4850828 0.68
SCHEMBL2435048 0.67 PSMB8 (0.38) PSMB8MAT2AHSD11B1KMT2APTPN1
SCHEMBL7292482 0.65 KDM4E (0.39) KMT2ADAOHSD17B10KDM4EHCRTR1
SCHEMBL7974006 0.65 ALDH1A1 (0.32) CYP3A4SMN1; SMN2HSD17B10
SCHEMBL1093444 0.64 CYP2A6 (0.53) PSMB8L3MBTL1PTPN1KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016007837-A1 CARBONYL LINKED BICYCLIC HETEROARYL ANTIBIOTIC TOLERANCE INHIBITORS SPERO THERAPEUTICS, INC. (US) 2016-01-14 WO claimed
US-7323488-B2 Chromogenic enzyme substrates BURTON MICHAEL 2008-01-29 US claimed
EP-1436411-B1 CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY BURTON MICHAEL (GB) 2005-12-14 EP claimed
US-20050124556-A1 Chromogenic enzyme substrates BURTON MICHAEL (GB) 2005-06-09 US claimed
EP-1436411-A2 CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY Burton, Michael (GB) 2004-07-14 EP claimed
WO-2003035896-A2 CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY BURTON MICHAEL (GB) 2003-05-01 WO claimed
CN-106467481-B The synthetic method of indoles -3- aryl ketone derivatives 昆明学院 2019-06-25 CN disclosed
CN-106467481-A The synthetic method of indole 3 aryl ketone derivatives 昆明学院 2017-03-01 CN disclosed
US-7323488-B2 Chromogenic enzyme substrates BURTON MICHAEL 2008-01-29 US disclosed
EP-1436411-B1 CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY BURTON MICHAEL (GB) 2005-12-14 EP disclosed
US-20050124556-A1 Chromogenic enzyme substrates BURTON MICHAEL (GB) 2005-06-09 US disclosed
EP-1436411-A2 CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY Burton, Michael (GB) 2004-07-14 EP disclosed
WO-2003035896-A2 CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY BURTON MICHAEL (GB) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124556-A1 Chromogenic enzyme substrates DCXR, MGAM, IDE PSMB8 3578/4885MAT2A 2580/4885HSD11B1 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.